

Sridhar Nimmagadda

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5465164/publications.pdf>

Version: 2024-02-01

75
papers

5,066
citations

94381

37
h-index

88593

70
g-index

80
all docs

80
docs citations

80
times ranked

7325
citing authors

#	ARTICLE	IF	CITATIONS
1	The Intricate Role of CXCR4 in Cancer. <i>Advances in Cancer Research</i> , 2014, 124, 31-82.	1.9	496
2	Small Molecule Inhibitor of NRF2 Selectively Intervenes Therapeutic Resistance in KEAP1-Deficient NSCLC Tumors. <i>ACS Chemical Biology</i> , 2016, 11, 3214-3225.	1.6	364
3	2-(3-{1-Carboxy-5-[(6-[¹⁸ F]Fluoro-Pyridine-3-Carbonyl)-Amino]-Pentyl}-Ureido)-Pentanedioic Acid, [¹⁸ F]DCFPyL, a PSMA-Based PET Imaging Agent for Prostate Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 7645-7653.	3.2	331
4	Bifunctional immune checkpoint-targeted antibody-ligand traps that simultaneously disable TGF β 2 enhance the efficacy of cancer immunotherapy. <i>Nature Communications</i> , 2018, 9, 741.	5.8	238
5	⁶⁸ Ga-Labeled Inhibitors of Prostate-Specific Membrane Antigen (PSMA) for Imaging Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2010, 53, 5333-5341.	2.9	196
6	Radiohalogenated Prostate-Specific Membrane Antigen (PSMA)-Based Ureas as Imaging Agents for Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 7933-7943.	2.9	180
7	A Convenient Method of Synthesis of <i>Bis</i> -Indolymethanes: Indium Trichloride Catalyzed Reactions of Indole with Aldehydes and Schiff's Bases. <i>Synthetic Communications</i> , 2000, 30, 1609-1614.	1.1	174
8	A humanized antibody for imaging immune checkpoint ligand PD-L1 expression in tumors. <i>Oncotarget</i> , 2016, 7, 10215-10227.	0.8	158
9	Single Dose Pharmacokinetics of Oral Tenofovir in Plasma, Peripheral Blood Mononuclear Cells, Colonic Tissue, and Vaginal Tissue. <i>AIDS Research and Human Retroviruses</i> , 2013, 29, 1443-1450.	0.5	134
10	Rapid PD-L1 detection in tumors with PET using a highly specific peptide. <i>Biochemical and Biophysical Research Communications</i> , 2017, 483, 258-263.	1.0	132
11	PD-L1 Detection in Tumors Using [⁶⁴ Cu]Atezolizumab with PET. <i>Bioconjugate Chemistry</i> , 2016, 27, 2103-2110.	1.8	128
12	Hypoxia Regulates CD44 and Its Variant Isoforms through HIF-1 α in Triple Negative Breast Cancer. <i>PLoS ONE</i> , 2012, 7, e44078.	1.1	125
13	Molecular Imaging of CXCR4 Receptor Expression in Human Cancer Xenografts with [⁶⁴ Cu]AMD3100 Positron Emission Tomography. <i>Cancer Research</i> , 2010, 70, 3935-3944.	0.4	118
14	Sequential SPECT and Optical Imaging of Experimental Models of Prostate Cancer with a Dual Modality Inhibitor of the Prostate-Specific Membrane Antigen. <i>Angewandte Chemie - International Edition</i> , 2011, 50, 9167-9170.	7.2	106
15	⁶⁴ Cu-Labeled Inhibitors of Prostate-Specific Membrane Antigen for PET Imaging of Prostate Cancer. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 2657-2669.	2.9	103
16	Peptide-Based ⁶⁸ Ga-PET Radiotracer for Imaging PD-L1 Expression in Cancer. <i>Molecular Pharmaceutics</i> , 2018, 15, 3946-3952.	2.3	102
17	Human Cancer Cell Membrane-Coated Biomimetic Nanoparticles Reduce Fibroblast-Mediated Invasion and Metastasis and Induce T-Cells. <i>ACS Applied Materials & Interfaces</i> , 2019, 11, 7850-7861.	4.0	98
18	PSMA-Targeted Theranostic Nanoplex for Prostate Cancer Therapy. <i>ACS Nano</i> , 2012, 6, 7752-7762.	7.3	95

#	ARTICLE	IF	CITATIONS
19	Peptide-based PET quantifies target engagement of PD-L1 therapeutics. <i>Journal of Clinical Investigation</i> , 2019, 129, 616-630.	3.9	94
20	Heterogeneous expression of PD-L1 in pulmonary squamous cell carcinoma and adenocarcinoma: implications for assessment by small biopsy. <i>Modern Pathology</i> , 2017, 30, 530-538.	2.9	92
21	Imaging of Musculoskeletal Bacterial Infections by [124I]FIAU-PET/CT. <i>PLoS ONE</i> , 2007, 2, e1007.	1.1	86
22	Transforming Thymidine into a Magnetic Resonance Imaging Probe for Monitoring Gene Expression. <i>Journal of the American Chemical Society</i> , 2013, 135, 1617-1624.	6.6	80
23	Imaging CXCR4 Expression in Human Cancer Xenografts: Evaluation of Monocyclam ⁶⁴ Cu-AMD3465. <i>Journal of Nuclear Medicine</i> , 2011, 52, 986-993.	2.8	75
24	Immunoimaging of CXCR4 Expression in Brain Tumor Xenografts Using SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2009, 50, 1124-1130.	2.8	64
25	Bacterial Thymidine Kinase as a Non-Invasive Imaging Reporter for <i>Mycobacterium tuberculosis</i> in Live Animals. <i>PLoS ONE</i> , 2009, 4, e6297.	1.1	59
26	Effect of Chelators on the Pharmacokinetics of ^{99m} Tc-Labeled Imaging Agents for the Prostate-Specific Membrane Antigen (PSMA). <i>Journal of Medicinal Chemistry</i> , 2013, 56, 6108-6121.	2.9	57
27	First-in-Humans Evaluation of a PD-L1-Binding Peptide PET Radiotracer in Non-Small Cell Lung Cancer Patients. <i>Journal of Nuclear Medicine</i> , 2022, 63, 536-542.	2.8	56
28	Development of [¹⁸ F]FPy-WL12 as a PD-L1 Specific PET Imaging Peptide. <i>Molecular Imaging</i> , 2019, 18, 153601211985218.	0.7	52
29	[⁶⁴ Cu]XYIMSR-06: A dual-motif CAIX ligand for PET imaging of clear cell renal cell carcinoma. <i>Oncotarget</i> , 2016, 7, 56471-56479.	0.8	49
30	Preclinical Evaluation of an ¹³¹ I-Labeled Benzamide for Targeted Radiotherapy of Metastatic Melanoma. <i>Cancer Research</i> , 2010, 70, 4045-4053.	0.4	48
31	Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy. <i>Molecular Imaging</i> , 2017, 16, 153601211771845.	0.7	47
32	Imaging of carbonic anhydrase IX with an ¹¹¹ In-labeled dual-motif inhibitor. <i>Oncotarget</i> , 2015, 6, 33733-33742.	0.8	44
33	Salicylic Acid Conjugated Dendrimers Are a Tunable, High Performance CEST MRI NanoPlatform. <i>Nano Letters</i> , 2016, 16, 2248-2253.	4.5	43
34	A Robust Approach to Enhance Tumor-selective Accumulation of Nanoparticles. <i>Oncotarget</i> , 2011, 2, 59-68.	0.8	40
35	CXCR4-Based Imaging Agents. <i>Journal of Nuclear Medicine</i> , 2011, 52, 1665-1669.	2.8	39
36	A PSMA-targeted theranostic agent for photodynamic therapy. <i>Journal of Photochemistry and Photobiology B: Biology</i> , 2017, 167, 111-116.	1.7	39

#	ARTICLE	IF	CITATIONS
37	[¹⁸ F]Fluorobenzoyllysinepentanedioic Acid Carbamates: New Scaffolds for Positron Emission Tomography (PET) Imaging of Prostate-Specific Membrane Antigen (PSMA). <i>Journal of Medicinal Chemistry</i> , 2016, 59, 206-218.	2.9	37
38	Detection of Dose Response in Chronic Doxorubicin-Mediated Cell Death with Cardiac Technetium 99m Annexin V Single-Photon Emission Computed Tomography. <i>Molecular Imaging</i> , 2008, 7, 7290.2008.00015.	0.7	36
39	Quantifying PD-L1 Expression to Monitor Immune Checkpoint Therapy: Opportunities and Challenges. <i>Cancers</i> , 2020, 12, 3173.	1.7	36
40	Preclinical Evaluation of ⁸⁶ Y-Labeled Inhibitors of Prostate-Specific Membrane Antigen for Dosimetry Estimates. <i>Journal of Nuclear Medicine</i> , 2015, 56, 628-634.	2.8	35
41	Distribution of Cell-Free and Cell-Associated HIV Surrogates in the Colon After Simulated Receptive Anal Intercourse in Men Who Have Sex With Men. <i>Journal of Acquired Immune Deficiency Syndromes</i> (1999), 2012, 59, 10-17.	0.9	34
42	A fully human CXCR4 antibody demonstrates diagnostic utility and therapeutic efficacy in solid tumor xenografts. <i>Oncotarget</i> , 2016, 7, 12344-12358.	0.8	32
43	Evaluation of PSMA-Targeted PAMAM Dendrimer Nanoparticles in a Murine Model of Prostate Cancer. <i>Molecular Pharmaceutics</i> , 2019, 16, 2590-2604.	2.3	29
44	Distribution of Cell-Free and Cell-Associated HIV Surrogates in the Female Genital Tract After Simulated Vaginal Intercourse. <i>Journal of Infectious Diseases</i> , 2012, 205, 725-732.	1.9	28
45	Targeted Imaging of the Atypical Chemokine Receptor 3 (ACKR3/CXCR7) in Human Cancer Xenografts. <i>Journal of Nuclear Medicine</i> , 2016, 57, 981-988.	2.8	28
46	Targeted Molecular Imaging in Oncology: Focus on Radiation Therapy. <i>Seminars in Radiation Oncology</i> , 2008, 18, 136-148.	1.0	27
47	Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging. <i>Journal of Nuclear Medicine</i> , 2018, 59, 486-493.	2.8	27
48	Ovarian Cancer Targeted Theranostics. <i>Frontiers in Oncology</i> , 2019, 9, 1537.	1.3	27
49	Metabolic Signatures Imaged in Cancer-Induced Cachexia. <i>Cancer Research</i> , 2011, 71, 6948-6956.	0.4	26
50	Bridged cyclams as imaging agents for chemokine receptor 4 (CXCR4). <i>Nuclear Medicine and Biology</i> , 2014, 41, 552-561.	0.3	25
51	In vivo Evaluation of an Engineered Cyclotide as Specific CXCR4 Imaging Reagent. <i>Chemistry - A European Journal</i> , 2017, 23, 14469-14475.	1.7	25
52	Pharmacodynamic Markers for Choline Kinase Down-regulation in Breast Cancer Cells. <i>Neoplasia</i> , 2009, 11, 477-484.	2.3	23
53	Immune Modulation Therapy and Imaging: Workshop Report. <i>Journal of Nuclear Medicine</i> , 2018, 59, 410-417.	2.8	23
54	Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 4059-4070.	2.9	22

#	ARTICLE	IF	CITATIONS
55	Pharmacodynamic measures within tumors expose differential activity of PD(L)-1 antibody therapeutics. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	21
56	The role of DNA synthesis imaging in cancer in the era of targeted therapeutics. Cancer and Metastasis Reviews, 2008, 27, 575-587.	2.7	18
57	Molecular Imaging of Conscious, Unrestrained Mice with AwakeSPECT. Journal of Nuclear Medicine, 2013, 54, 969-976.	2.8	18
58	Biodistribution, PET, and Radiation Dosimetry Estimates of HSV-tk Gene Expression Imaging Agent 1-(2'-Deoxy-2'- ¹⁸ F-Fluoro- β -D-Arabinofuranosyl)-5-Iodouracil in Normal Dogs. Journal of Nuclear Medicine, 2007, 48, 655-660.	2.8	17
59	Development of prostate specific membrane antigen targeted ultrasound microbubbles using bioorthogonal chemistry. PLoS ONE, 2017, 12, e0176958.	1.1	14
60	Structural Characterization and in Vivo Evaluation of β -Hairpin Peptidomimetics as Specific CXCR4 Imaging Agents. Molecular Pharmaceutics, 2015, 12, 941-953.	2.3	13
61	Biodistribution and radiation dosimetry estimates of 1-(2'-deoxy-2'-(¹⁸ F-Fluoro-1- β -D-arabinofuranosyl)-5-bromouracil): PET imaging studies in dogs. Journal of Nuclear Medicine, 2005, 46, 1916-22.	2.8	12
62	Imaging α 4 β 2 Nicotinic Acetylcholine Receptors (nAChRs) in Baboons with [¹⁸ F]XTRA, a Radioligand with Improved Specific Binding in Extra-Thalamic Regions. Molecular Imaging and Biology, 2017, 19, 280-288.	1.3	11
63	Evaluation of Musculoskeletal and Pulmonary Bacterial Infections With [¹²⁴ I]FIAU PET/CT. Molecular Imaging, 2020, 19, 153601212093687.	0.7	11
64	Effects of Recombinant Human Thyroid-Stimulating Hormone Superagonists on Thyroidal Uptake of ¹⁸ F-Fluorodeoxyglucose and Radioiodide. Thyroid, 2011, 21, 783-792.	2.4	9
65	Imaging Axl expression in pancreatic and prostate cancer xenografts. Biochemical and Biophysical Research Communications, 2014, 443, 635-640.	1.0	9
66	SNP2SIM: a modular workflow for standardizing molecular simulation and functional analysis of protein variants. BMC Bioinformatics, 2019, 20, 171.	1.2	7
67	Herpes simplex virus thymidine kinase imaging in mice with (1-(2-deoxy-2- ¹⁸ F-fluoro-1- β -D-arabinofuranosyl)-5-iodouracil) and metabolite (1-(2-deoxy-2- ¹⁸ F-fluoro-1- β -D-arabinofuranosyl)-5-uracil). European Journal of Nuclear Medicine and Molecular Imaging, 2009, 36, 1987-1993.	3.3	6
68	Molecular Imaging of CXCL12 Promoter-driven HSV1-TK Reporter Gene Expression. Biotechnology and Bioprocess Engineering, 2018, 23, 208-217.	1.4	6
69	Differential Expression of Chemokine Receptors and their Roles in Cancer Imaging. Frontiers in Oncology, 2012, 2, 46.	1.3	5
70	PD-L1 near Infrared Photoimmunotherapy of Ovarian Cancer Model. Cancers, 2022, 14, 619.	1.7	4
71	Imaging Virus-Associated Cancer. Current Pharmaceutical Design, 2008, 14, 3048-3065.	0.9	3
72	Translational Applications of Protein Structure Simulation: Predicting Phenotype of Missense Variants. Biophysical Journal, 2019, 116, 13a.	0.2	3

#	ARTICLE	IF	CITATIONS
73	Process validation, current good manufacturing practice production, dosimetry, and toxicity studies of the carbonic anhydrase IX imaging agent [¹¹¹ In]Inâ€”YIMSRSâ€”1 for phase I regulatory approval. Journal of Labelled Compounds and Radiopharmaceuticals, 2021, 64, 243-250.	0.5	2
74	The new frontiers of multimodality and multi-isotope imaging. , 2014, , .		1
75	Imaging PD-L1 expression in melanoma brain metastases. Journal of Nuclear Medicine, 2021, , jnumed.121.263209.	2.8	0